1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Dermira’s Lebrikizumab Data Set Up Atopic Dermatitis Showdown With Dupixent

 
• By Joseph Haas

Dermira hopes to move into Phase III quickly with IL-13 inhibitor lebrikizumab, looking at monthly dosing in the maintenance setting. Efficacy in Phase IIb appears similar to Sanofi/Regeneron’s Dupixent.

Atopic Dermatitis

Dermira Inc.’s Phase IIb data for its IL-13 inhibitor lebrikizumab in atopic dermatitis showed efficacy across three dosing regimens, with a profile similar to market leader Dupixent. Now, the company hopes to initiate a Phase III study by year’s end that could set up the therapy with a dosing-convenience advantage compared to Sanofi/Regeneron Pharmaceuticals Inc.’s IL-4/IL-13 receptor antagonist.

Dupixent (dupilumab) became the first biologic approved for atopic dermatitis in 2017, and in its first full year on the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

More from R&D